AroCell Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

AroCell şirketinin toplam hissedar öz sermayesi SEK130.2M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK143.3M ve SEK13.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 44.54m
Eşitlik	SEK 130.21m
Toplam yükümlülükler	SEK 13.05m
Toplam varlıklar	SEK 143.26m

Son finansal sağlık güncellemeleri

Recent updates

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

Apr 20

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Feb 27

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Nov 07

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

Aug 10

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

Apr 18

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Jan 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AROC 'nin kısa vadeli varlıkları ( SEK65.8M ) kısa vadeli yükümlülüklerini ( SEK13.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: AROC un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AROC borçsuzdur.

Borcun Azaltılması: AROC un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AROC şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: AROC tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

AroCell Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Recent updates

AroCell Announces New Study Published on the Prognostic Value of sTK1 in Prostate Cancer

Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)

AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024

AroCell AB (publ), Annual General Meeting, May 22, 2024

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

Now 22% undervalued after recent price drop

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)

AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

Consensus revenue estimates fall by 12%

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)

New major risk - Market cap size

AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

New major risk - Market cap size

Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)

Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)

Price target decreased to kr2.30

High number of new and inexperienced directors

Consensus revenue estimates increase by 17%

Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)

AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market

First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)

Price target decreased to kr2.00

High number of new directors

AroCell AB (publ) Announces CFO Changes

Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)

High number of new directors

AroCell AB (publ), Annual General Meeting, May 24, 2022

Head of Operations recently bought kr81k worth of stock

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)

AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.

Chief Commercial Officer has left the company

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

New 90-day high: kr3.41

Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)

AroCell AB (publ), Annual General Meeting, May 06, 2021

Head of Operations recently bought kr91k worth of stock

Head of Operations recently bought kr91k worth of stock

AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical Officer

AroCell AB (publ) Appoints Anders Hultman as CEO

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

New 90-day low: kr2.43

Earnings released

New 90-day high - kr3.64

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin